GALACTOSEMIA

Galactosemia — a neonatal metabolic emergency where lactose from breast milk or formula causes liver failure, sepsis, and brain damage in the first days of life in untreated infants with GALT deficiency.

Whole genome sequencing identifies the complete GALT genotype — including compound heterozygous combinations that determine long-term outcome variability — providing the precise molecular diagnosis that newborn screening enzyme assays do not supply.

GALT

About this condition

Galactosemia

Classic galactosemia is an autosomal recessive inborn error of galactose metabolism caused by pathogenic variants in GALT (galactose-1-phosphate uridylyltransferase) on chromosome 9p13.3. GALT encodes the enzyme that converts galactose-1-phosphate and UDP-glucose to UDP-galactose and glucose-1-phosphate. Complete GALT deficiency leads to galactose-1-phosphate accumulation, which is toxic to the liver, kidneys, brain, and gonads. Classic galactosemia affects approximately 1 in 40,000-60,000 newborns in populations of Northern European ancestry. Duarte galactosemia — caused by the N314D variant (Duarte 2 allele) in compound heterozygosity with a classic pathogenic allele — is more common (approximately 1 in 4,000) and produces only partial enzyme deficiency with generally benign clinical outcomes.

Classical galactosemia presents in the neonatal period as a life-threatening crisis: jaundice, hepatomegaly, hypoglycemia, coagulopathy, renal tubular dysfunction, and a particular susceptibility to E. coli neonatal sepsis develop within days of initiating milk feeding. Without immediate dietary galactose elimination (discontinuation of human milk and transition to soy-based or elemental formula), untreated infants develop liver failure, permanent brain damage, and death. Newborn screening by enzyme assay or total galactose measurement identifies most affected infants before symptom onset; prompt dietary management in the first week of life prevents the neonatal crisis.

Despite successful acute management, long-term outcomes in classic galactosemia are frequently impaired: speech and language difficulties, intellectual disability of variable degree, neuromotor problems, and primary ovarian insufficiency (POI) — affecting approximately 80% of affected females regardless of dietary management — represent a chronic disease burden that dietary restriction alone does not prevent. Genotype-phenotype correlations exist: homozygous p.Gln188Arg variants (the most common classic allele in Europeans) are associated with worse long-term neurodevelopmental outcomes compared to some compound heterozygous genotypes. This prognosis counseling requires precise GALT genotyping beyond the enzyme assay that newborn screening programs use.

Duarte galactosemia (GALT N314D in compound heterozygosity with a classic allele) produces only 25% residual enzyme activity. Current evidence supports that Duarte galactosemia does not require dietary restriction in most cases — but distinguishing Duarte from classic galactosemia requires molecular genotyping.

Gene locus: GALT (9p13.3)

Newborn screening provides an enzyme activity result. It does not identify the specific GALT variants — and without the genotype, clinicians cannot distinguish classic from Duarte galactosemia or provide accurate long-term prognosis.

Enzyme screening does not tell you which GALT variants are present — and that matters for lifetime prognosis

Newborn screening programs for galactosemia measure total galactose or GALT enzyme activity; they report an enzyme result, not a genotype. Without molecular GALT genotyping, clinicians cannot distinguish classic galactosemia from Duarte galactosemia — which has profoundly different dietary and prognostic implications. Classic galactosemia requires lifelong galactose restriction; Duarte galactosemia generally does not require dietary restriction. Additionally, within classic galactosemia, the specific genotype — homozygous p.Gln188Arg vs. compound heterozygous with a milder allele — provides information relevant to long-term neurodevelopmental outcome and ovarian insufficiency risk that enzyme activity alone cannot supply. Whole genome sequencing provides the complete GALT genotype.

Female carriers of classic alleles face primary ovarian insufficiency risk that requires proactive monitoring

Primary ovarian insufficiency (POI) develops in approximately 80% of females with classic galactosemia despite optimal dietary management — a consistent and poorly understood complication of the condition. The mechanism appears to involve direct galactose toxicity to oocytes and follicular development during fetal and early postnatal life. Recognizing POI risk early — which requires appropriate counseling beginning in adolescence about fertility preservation options and hormone replacement therapy needs — depends on having the correct galactosemia diagnosis confirmed by molecular testing. Carrier females (heterozygotes) also have some evidence of slightly elevated POI risk, though much less pronounced than in affected females.

Galactosemia — a neonatal metabolic emergency where lactose from breast milk or formula causes liver failure, sepsis, and brain damage in the first days of life in untreated infants with GALT deficiency.

Galactosemia

Newborn screening provides an enzyme activity result. It does not identify the specific GALT variants — and without the genotype, clinicians cannot distinguish classic from Duarte galactosemia or provide accurate long-term prognosis.

Enzyme screening does not tell you which GALT variants are present — and that matters for lifetime prognosis

Female carriers of classic alleles face primary ovarian insufficiency risk that requires proactive monitoring

Others in Rare Diseases

One test. A lifetime of answers.